Introduction: Niagen Bioscience Inc. (NASDAQ:NAGE) is recognized as one of the top consumer staples penny stocks.
On April 9, the company announced that its patented product, Nicotinamide Riboside Chloride, which is the active ingredient in its flagship offering, Niagen, received an official dietary supplement ingredient monograph from the United States Pharmacopeia.
Copyright: zneb076 / 123RF Stock Photo
Following this significant announcement, Rob Fried, the CEO, highlighted its importance for the entire NAD+ supplement industry. He noted that Nicotinamide Riboside (NR) is now the only ingredient in this category to have an official standard from the Pharmacopeia, while NMN and NAD+ still lack such validation. This development has created a favorable sentiment surrounding the stock, placing it among the most promising names in consumer staples.
Earlier, on March 10, the company revealed that it had secured US Patent No. 12,558,367 for Niagen. This expansion of intellectual property underscores the company’s commitment to building a competitive advantage in the field of longevity science. As natural cellular energy levels decline with age, the wellness sector is transitioning from basic supplements to more effective therapeutic delivery systems.
Rob Fried further emphasized that this patent provides vital intellectual property protection until 2044. It illustrates the company’s distinct approach in offering an improved aqueous-based solution under the new Niagen Plus brand, avoiding the discomfort often associated with traditional IV medications and allowing for significantly faster infusion times.
Niagen Bioscience Inc. (NASDAQ:NAGE) is dedicated to the development and commercialization of products aimed at combating the effects of aging. The firm focuses on dietary supplements that feature nicotinamide adenine dinucleotide (NAD+), along with pharmaceutical- and food-grade Niagen and its precursor, nicotinamide riboside. The company distributes its products through various channels, including e-commerce, specialized retailers, and licensed healthcare partners.
While Niagen shows promise as an investment, there are certain AI stocks that may offer even greater upside potential at a lower risk. For those interested in a highly undervalued AI stock that stands to gain from recent trends in tariffs and onshoring, we invite you to explore our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Conclusion: Niagen Bioscience Inc. is making significant strides in the aging product market, showcasing innovation and commitment to quality. As the company continues to navigate the evolving landscape of health supplements, it remains to be seen how these developments will impact its stock performance moving forward.
Disclosure: None. Follow Insider Monkey on Google News.
